Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2b + placebo
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Intralesional, Intrapleural
01
Overview
This is a combination therapy consisting of recombinant human interferon alfa-2b and an inert substance (placebo). Interferon alfa-2b is a type I recombinant protein produced by Escherichia coli using recombinant DNA technology. It acts as an immunomodulator, antiviral, and antineoplastic agent. Its mechanism involves binding to cell surface receptors, activating the JAK/STAT pathway, and inducing the expression of genes that inhibit viral replication and modulate immune responses. Interferon alfa-2b is used in the treatment of chronic hepatitis B and C infections, hairy cell leukemia, follicular lymphoma, malignant melanoma (especially as adjuvant therapy), AIDS-related Kaposi's sarcoma, and genital warts. The addition of a placebo serves as a control in clinical trials to assess the efficacy or safety profile of interferon alfa-2b[1][3][5][8].
- Brand names
- Intron A + placebo
- Other names
- interferon alpha 2b + placebointerferon α-2b + placeborIFN-alpha-2b + placeborecombinant human interferon alpha 2b + placebo
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2b + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2b + placebo.